EPS for Alliqua BioMedical, Inc. (ALQA) Expected At $5.20

April 22, 2018 - By Michael Collier

Alliqua BioMedical, Inc. (NASDAQ:ALQA) Logo

Analysts expect Alliqua BioMedical, Inc. (NASDAQ:ALQA) to report $5.20 EPS on May, 8.They anticipate $7.10 EPS change or 373.68 % from last quarter’s $-1.9 EPS. ALQA’s profit would be $26.03 million giving it 0.11 P/E if the $5.20 EPS is correct. The stock increased 3.14% or $0.07 during the last trading session, reaching $2.3. About 22,728 shares traded. Alliqua BioMedical, Inc. (NASDAQ:ALQA) has declined 69.15% since April 22, 2017 and is downtrending. It has underperformed by 80.70% the S&P500.

Alliqua BioMedical, Inc., a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company has market cap of $11.51 million. It markets MIST Ultrasound Healing Therapy, a painless, noncontact, low-frequency ultrasound to promote healing; Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix that are human biologic regenerative technologies; and TheraBond 3D Antimicrobial Barrier Systems that promotes an optimal wound healing by creating an antimicrobial barrier that helps protect against infection. It currently has negative earnings. The firm also provides contract manufacturing services, including the development, manufacture, and market of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.